CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Gilead Sciences, Inc.

GILD
$187.53BLarge Cap

Next catalyst

PDUFAFeb 2, 2027in 74 days

Lenacapavir

HIV pre-exposure prophylaxis (PrEP)

Get an email about GILD's next catalysts

Track Gilead Sciences (GILD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 20 more upcoming events in our data (Phase 2 readout, partnership, Phase 3 readout).See the timeline

Catalyst Timeline

21 upcoming, 3 past

Phase 2

Sacituzumab Govitecan (SG) Phase 2 Est. Readout

December 2026~Sacituzumab Govitecan (SG)23

Estimated primary completion for Sacituzumab Govitecan (SG) trial (NCT06682728) in Urothelial Carcinoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Zimberelimab Phase 2 Est. Readout

December 2026~Zimberelimab33

Estimated primary completion for Zimberelimab trial (NCT06048133) in Biliary Tract Carcinoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Remdesivir (RDV) Phase 2 Est. Readout (COVIDKIDNEY)

December 2026~Remdesivir (RDV)15

Estimated primary completion for Remdesivir (RDV) trial (NCT07197164) in COVID - 19. Topline data typically follows completion by weeks to months.

Source
Phase 2

Sacituzumab Govitecan Phase 2 Est. Readout

December 2026~Sacituzumab Govitecan27

Estimated primary completion for Sacituzumab Govitecan trial (NCT05675579) in Breast Cancer. Topline data typically follows completion by weeks to months.

Source
Partnership

Partnership - Gamgertamig

January 2027~

Galapagos and Gilead announced a partnership on Gamgertamig with Galapagos receiving $500M in upfront cash, with registrational trials anticipated in 2027.

Phase 3

Sacituzumab Govitecan Phase 3 Est. Readout

January 2027~Sacituzumab Govitecan614

Estimated primary completion for Sacituzumab Govitecan trial (NCT05609968) in Carcinoma, Non-Small-Cell Lung. Topline data typically follows completion by weeks to months.

Source
Phase 2

Tilpisertib Fosmecarbil Phase 2 Est. Readout (PALEKONA)

January 2027~Tilpisertib Fosmecarbil176

Primary completion for Tilpisertib Fosmecarbil trial (NCT06029972) in Ulcerative Colitis

Source
Phase 2

Anti-OX40 Antibody PF-04518600 Phase 2 Est. Readout (InCITe)

January 2027~Anti-OX40 Antibody PF-04518600145

Estimated primary completion for Anti-OX40 Antibody PF-04518600 trial (NCT03971409) in Stage III Breast Cancer. Topline data typically follows completion by weeks to months.

Source

Upcoming FDA decisions

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Pharmaceutics🇺🇸North AmericaFOSTER CITY17.0K employees

Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.

Website
Drug Pipeline

Trodelvy

Sacituzumab Govitecan

Approved

Triple-Negative Breast Cancer

Fast TrackBreakthrough

MTX

Phase 3

Rheumatoid Arthritis

Sustiva (Efavirenz)

Phase 3

HIV Infections

abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)

Phase 3

HIV

Epivir (Lamivudine)

Phase 3

HIV Infections

Antiretroviral medications

Phase 3

HIV Infections

Antiretroviral medications+Isoniazid prophylaxis

Phase 3

HIV Infections

TAF/FTC/fixed-dose combination

Phase 3

HIV/AIDS

B/F/TAF (TOS)

Phase 3

HIV-1 Infection

B/F/TAF (Low Dose)

Phase 3

HIV-1 Infection

Zimberelimab

Phase 3

Head and Neck Squamous Cell Carcinoma

Stribild

Phase 3

Acquired Immunodeficiency Syndrome

Sacituzumab Govitecan (SG)

Phase 3

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Baseline DRV- containing ARV regimen

Phase 3

HIV-1

RTV

Phase 3

Acquired Immunodeficiency Syndrome

Seladelpar

Phase 3

Primary Biliary Cholangitis

Current failing ARV regimen

Phase 3

HIV

Adefovir Dipivoxil (ADV)

Phase 3

Chronic Hepatitis B

ABC/DTG/3TC

Phase 3

HIV-1 Infection

Axicabtagene Ciloleucel

Phase 3

High-risk Large B-cell Lymphoma (LBCL)

ABC/3TC

Phase 3

HIV-1 Infection

Elvitegravir

Phase 3

HIV Infection

nebulised liposomal amphotericin B

Phase 3

Aspergillosis

GS-4182

Phase 3

HIV-1-Infection

F/R/TAF

Phase 3

HIV-1 Infection

Stable Baseline Regimen

Phase 3

HIV-1-infection

Remdesivir

Phase 3

COVID-19

Zidovudine

Phase 3

HIV Infections

Adefovir Dipivoxil for

Phase 3

Chronic Hepatitis B

Platinum-containing Salvage Chemotherapy

Phase 3

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Tobramycin inhalation solution

Phase 3

Cystic Fibrosis

Lenacapavir Tablet

Phase 3

HIV Pre-exposure Prophylaxis

F/TAF

Phase 3

HIV-1 Infection

EVG/COBI/FTC/TDF

Phase 3

Acquired Immunodeficiency Syndrome

EFV/FTC/TDF

Phase 3

HIV

Subcutaneous Lenacapavir

Phase 3

HIV-1-infection

NRTIs

Phase 3

HIV-1 Infection

TAF

Phase 3

HBeAg-positive Chronic Hepatitis B

Background regimen

Phase 3

HIV Infection

RBV

Phase 3

Hepatitis C Virus Infection

Atripla

Phase 3

HIV

Lepetegravir/Lenacapavir pacfosacil FDC

Phase 3

HIV-1-Infection

GS-3242 Injection

Phase 3

HIV-1-infection

COBI

Phase 3

Acquired Immunodeficiency Syndrome

Lepetegravir

Phase 3

HIV-1-Infection

Lenacapavir pacfosacil

Phase 3

HIV-1-Infection

Adenosine

Phase 3

Coronary Artery Disease

Tenofovir disoproxil fumarate

Phase 3

Chronic Hepatitis B

Boosted PIs

Phase 3

HIV-1

Tobramycin Inhalation Solution (TIS)

Phase 3

Cystic Fibrosis

PEGASYS (Interféron pégylé alpha -2a)

Phase 3

Hepatitis B

PTM B/F/TAF

Phase 3

HIV-1-infection

B/F/TAF (Adult Strength)

Phase 3

HIV-1 Infection

FTC/RPV/TDF

Phase 3

HIV-1 Infection

E/C/F/TAF

Phase 3

HIV

Tenofovir disoproxil fumarate (TDF)

Phase 3

Hepatitis B Virus (HBV)

Teropavimab

Phase 3

HIV Infection

SOF

Phase 3

Hepatitis C

BIC/LEN FDC

Phase 3

HIV-1-infection

FTC/TDF

Phase 3

Chronic Hepatitis B

Oral Lenacapavir

Phase 3

HIV-1-infection

Ranolazine

Phase 3

Type 2 Diabetes Mellitus

AZLI

Phase 3

Cystic Fibrosis

Tenofovir DF

Phase 3

HIV Infections

B/F/TAF

Phase 3

HIV-1-infection

F/TDF

Phase 3

Pre-Exposure Prophylaxis of HIV-1 Infection

MBX-102

Phase 3

Type 2 Diabetes

Filgotinib

Phase 3

Ulcerative Colitis

Aztreonam for Inhalation Solution (AZLI)

Phase 3

Cystic Fibrosis

Idelalisib

Phase 3

Hodgkin Lymphoma

SOF/VEL

Phase 3

Hepatitis C Virus Infection

Sacituzumab govitecan-hziy (SG)

Phase 3

Triple Negative Breast Cancer

Peg-IFN

Phase 3

Hepatitis C

Sacituzumab Govitecan-hziy

Phase 3

Triple Negative Breast Cancer

DRV/co

Phase 3

HIV-1 Infection

SBR

Phase 3

HIV-1-infection

csDMARDs

Phase 3

Rheumatoid Arthritis

ADV

Phase 3

Chronic Hepatitis B

Zinlirvimab

Phase 3

HIV-1-infection

Lenacapavir Injection

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

Tenofovir Alafenamide

Phase 3

Chronic Hepatitis B

AmBisome

Phase 3

Invasive Aspergillosis

DTG

Phase 3

HIV-1/HBV Co-Infection

Anitocabtagene Autoleucel

Phase 3

Multiple Myeloma

Liposomal amphotericin B

Phase 3

Invasive Fungal Disease

ATV/co

Phase 3

HIV-1 Infection

Andecaliximab

Phase 3

Gastric Adenocarcinoma

Domvanalimab

Phase 3

Advanced Non-Small Cell Lung Cancer

Eribulin

Phase 3

Metastatic Breast Cancer

E/C/F/TDF

Phase 3

HIV

PI

Phase 3

HIV-1 Infection

TDF

Phase 3

Chronic Hepatitis B

LDV/SOF

Phase 3

Chronic Hepatitis C Virus

ambrisentan

Phase 3

Pulmonary Hypertension

Optimized Background Regimen (OBR)

Phase 3

HIV-1-infection

Eribulin Mesylate Injection

Phase 3

Metastatic Breast Cancer

Viread (tenofovir disoproxil fumarate)

Phase 3

HIV Infections

KITE-753

Phase 3

Relapsed or Refractory Large B-cell Lymphoma

GS-1720

Phase 3

HIV-1-infection

AZLI two times

Phase 3

Cystic Fibrosis

Cobicistat

Phase 3

Acquired Immune Deficiency Syndrome (AIDS)

SOF/VEL/VOX

Phase 3

Hepatitis C Virus Infection

NNRTI

Phase 3

Acquired Immunodeficiency Syndrome

Obeldesivir

Phase 3

COVID-19

PEG

Phase 3

Hepatitis C

Bictegravir

Phase 3

HIV-1-infection

Sofosbuvir

Phase 3

Hepatitis C, Chronic

E/C/F/TAF (Low Dose)

Phase 3

Acquired Immune Deficiency Syndrome (AIDS)

ISL/LEN

Phase 3

HIV-1-Infection

Biktarvy

Phase 3

Human Immunodeficiency Virus

Ledipasvir/Sofosbuvir

Phase 3

Hepatitis C, Chronic

Bulevirtide

Phase 3

Chronic Hepatitis Delta

Darusentan

Phase 3

Hypertension

FTC

Phase 3

Chronic Hepatitis B

3rd ARV agent

Phase 3

HIV-1

Emtricitabine (FTC)

Phase 3

HIV Infections

DRV

Phase 3

HIV-1 Infection

AZLI three times

Phase 3

Cystic Fibrosis

Regadenoson

Phase 3

Coronary Artery Disease

ATV

Phase 3

HIV

FTC/RPV/TAF

Phase 3

HIV-1 Infection

Vinflunine

Phase 3

Locally Advanced or Metastatic Unresectable Urothelial Cancer

3TC

Phase 3

HIV-1 Infection

zidovudine and lamivudine (Combivir®)

Phase 3

HIV Infections

Subcutaneous (SC) Lenacapavir (LEN)

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

Failing ARV Regimen

Phase 3

HIV-1-infection

F/TAF (for US participants only)

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

LPV/r

Phase 3

Acquired Immune Deficiency Syndrome (AIDS)

Oral Lenacapavir (LEN)

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

Sub-cutaneous (SC) Lenacapavir (LEN)

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

Third Unboosted Drug

Phase 3

Acquired Immune Deficiency Syndrome (AIDS)

Cobicistat TOS

Phase 3

Acquired Immune Deficiency Syndrome (AIDS)

F/TAF TOS

Phase 3

Acquired Immune Deficiency Syndrome (AIDS)

PTM F/TDF

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

Ledipasvir-Sofosbuvir

Phase 3

Human Immunodeficiency Virus

PTM Oral LEN

Phase 3

Pre-Exposure Prophylaxis of HIV Infection

co-formulated TAF/FTC

Phase 3

HIV Infections

NRTI

Phase 3

Acquired Immunodeficiency Syndrome

GS-3242 Tablet

Phase 3

HIV-1-infection

Descovy or Truvada

Phase 3

HIV Infections

Harvoni

Phase 3

Hepatitis C

Tenofovir (TDF)

Phase 3

HIV Infection

emtricitabine and tenofovir DF

Phase 3

HIV Infections

raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine

Phase 3

HIV-1 Infections

enfuvirtide

Phase 3

HIV Infections

Sacituzumab Govitecan

Phase 3

Breast Cancer

Genvoya

Phase 3

HIV Risk

PTM ISL/LEN

Phase 3

HIV-1-infection

Single dose liposomal Amphotericin and Fluconazole

Phase 3

Cryptococcal Meningitis

Emtricitabine/tenofovir disoproxil fumarate

Phase 3

HIV Infection

Truvada

Phase 3

HIV Infections

Symtuza

Phase 3

HIV/AIDS

Aviptadil

Phase 3

Covid19

Bictegravir/Lenacapavir (BIC/LEN) FDC

Phase 3

HIV-1-infection

Corticosteroid

Phase 3

Covid19

Amrubicin (Japan only)

Phase 3

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Bictegravir/Lenacapavir

Phase 3

HIV-1-infection

Deferred Intervention Arm

Phase 3

HIV Prevention

Lurbinectedin (regions/countries where approved and available)

Phase 3

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Immediate Intervention Arm

Phase 3

HIV Prevention

Darunavir

Phase 3

HIV Infection

Efavirenz (EFV)

Phase 3

HIV Infections

FTC/TDF/EFV

Phase 3

HIV Infections

Rilpivirine/Emtricitabine/Tenofovir

Phase 3

HIV

Atazanavir

Phase 3

HIV Infection

Lenacapavir

Phase 3

HIV Prevention

Fast TrackBreakthroughPatent 2041

Magrolimab

Phase 3

Myelodysplastic Syndrome

OrphanFast TrackBreakthrough

didanosine, ddI (drug)

Phase 3

HIV Infections

efavirenz (drug)

Phase 3

HIV Infections

Cabotegravir Oral Tablet

Phase 3

HIV Infections

CAB LA

Phase 3

HIV Infections

Tenofovir Disoproxil Fumarate + Emtricitabine

Phase 3

HIV Infections

TDF/FTC tablets

Phase 3

HIV Infections

emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)

Phase 3

HIV

emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)

Phase 3

HIV

FIR

Phase 2

Nonalcoholic Steatohepatitis

Adefovir Dipivoxil

Phase 2

Hepatitis B

ISL

Phase 2

HIV-1 Infection

GS-9451

Phase 2

Hepatitis C, Chronic

KTE-C19

Phase 2

Refractory Diffuse Large B Cell Lymphoma

brexucabtagene autoleucel

Phase 2

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

emtricitabine/tenofovir alafenamide

Phase 2

Acceptability of Health Care

Quemliclustat

Phase 2

Biliary Tract Carcinoma

Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)

Phase 2

Chronic Hepatitis B

SIM

Phase 2

Non-Alcoholic Steatohepatitis (NASH)

Esmolol

Phase 2

Atrial Fibrillation

GS-9451 tablet

Phase 2

Chronic Genotype 1a or 1b HCV Infection

MVA.HTI

Phase 2

HIV/AIDS

Sacituzumab Govitecan-Hziy plus bevacizumab

Phase 2

NSCLC Stage IV

Levocarnitine

Phase 2

HIV Infections

ChAdOx1.HTI

Phase 2

HIV/AIDS

GS-9620

Phase 2

HIV/AIDS

Aztreonam for Inhalation (AI)

Phase 2

Cystic Fibrosis

Tilpisertib Fosmecarbil

Phase 2

Ulcerative Colitis

Therapeutic Hydrocortisone

Phase 2

Non-hodgkin Lymphoma

Etrumadenant

Phase 2

Metastatic Colorectal Cancer

Dronedarone

Phase 2

Atrial Fibrillation

Axi-cel

Phase 2

B Cell Lymphoma

MBX-2982

Phase 2

Diabetes

Other approved antivirals

Phase 2

Chronic Hepatitis B

Firsocostat

Phase 2

Nonalcoholic Steatohepatitis (NASH)

PTM CILO/FIR

Phase 2

Nonalcoholic Steatohepatitis

PTM SEMA

Phase 2

Nonalcoholic Steatohepatitis

ZDV/3TC

Phase 2

Hepatitis C

RAL

Phase 2

Hepatitis C

Levetiracetam

Phase 2

Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Peginterferon Alfa 2a

Phase 2

HCV Infection

TUB-040

Phase 2

Ovarian Cancer

LDV

Phase 2

Chronic Hepatitis C Infection

KITE-363

Phase 2

Relapsed and/or Refractory B-cell Lymphoma

D/C/F/TAF

Phase 2

Acquired Immunodeficiency Syndrome

GS-9876

Phase 2

Rheumatoid Arthritis

Simtuzumab

Phase 2

Primary Sclerosing Cholangitis (PSC)

Tecadenoson

Phase 2

Atrial Fibrillation

Tegobuvir (GS-9190)

Phase 2

Hepatitis C, Chronic

OAV Regimen

Phase 2

Chronic HBV Infection

emvistegrast

Phase 2

Ulcerative Colitis

GS-9190

Phase 2

HCV Infection

GS-9450

Phase 2

Nonalcoholic Steatohepatitis

Ledipasvir

Phase 2

Hepatitis B

emtricitabine, FTC (drug)

Phase 2

HIV Infections

Hepatitis B Immunoglobulin (HBIg)

Phase 2

Chronic Hepatitis B

GS-5885

Phase 2

Hepatitis C, Chronic

90Y-hLL2

Phase 2

NHL

MBX-8025

Phase 2

Hyperlipidemia

Vesatolimod

Phase 2

HIV-1-infection

Antibody-Drug Conjugates

Phase 2

Advanced or Metastatic Solid Tumour

Arhalofenate

Phase 2

Hyperuricemia

Copegus®

Phase 2

Hepatitis C, Chronic

veltuzumab

Phase 2

NHL

GS-5885 tablet

Phase 2

Hepatitis C, Chronic

Abacavir

Phase 2

HIV

GS-9137 - A Novel HIV-1 Integrase Inhibitor

Phase 2

HIV

VAS

Phase 2

Nonalcoholic Steatohepatitis (NASH)

Inavolisib (Dose #2)

Phase 2

Metastatic Breast Cancer

Tecartus

Phase 2

B-Cell Lymphoblastic Leukemia

Entecavir (ETV)

Phase 2

Chronic Hepatitis B

Cilofexor Dose B

Phase 2

Primary Biliary Cholangitis

Chemotherapy (Gemcitabine + Carboplatin or Eribulin)

Phase 2

Metastatic Breast Cancer

Emtricitabine/Tenofovir Disoproxil Oral Tablet

Phase 2

Acceptability of Health Care

GS-9674

Phase 2

Nonalcoholic Steatohepatitis (NASH)

anitocabtagene-autoleucel

Phase 2

Multiple Myeloma

Selicrelumab

Phase 2

Metastatic Breast Cancer

Ribociclib (Dose #2)

Phase 2

Metastatic Breast Cancer

Atirmociclib

Phase 2

Metastatic Breast Cancer

TUB-030

Phase 2

Advanced Solid Tumors

KTE-X19

Phase 2

Relapsed/Refractory Mantle Cell Lymphoma

Ribociclib (Dose #1)

Phase 2

Metastatic Breast Cancer

Inavolisib (Dose #1)

Phase 2

Metastatic Breast Cancer

FENO

Phase 2

Nonalcoholic Steatohepatitis (NASH)

Presatovir

Phase 2

Respiratory Syncytial Virus

CILO

Phase 2

Nonalcoholic Steatohepatitis (NASH)

Pegasys®

Phase 2

Chronic Hepatitis C Infection

PSI-7977 (GS7977)

Phase 2

Hepatitis C

Amprenavir

Phase 2

HIV Infections

GS-5734

Phase 2

Ebola

VDV

Phase 2

Hepatitis C Virus Infection

Tirabrutinib

Phase 2

Chronic Lymphocytic Leukemia

FTI, AZLI

Phase 2

Cystic Fibrosis

Liposomal amphotericin B + miltefosine

Phase 2

Primary Visceral Leishmaniasis

EFV

Phase 2

Hepatitis C

milatuzumab

Phase 2

Chronic Lymphocytic Lymphoma

Emtricitabine

Phase 2

HIV Infections

MBX-8025 (Dose Escalation Period 1)

Phase 2

Homozygous Familial Hypercholesterolemia

Tegobuvir

Phase 2

Hepatitis C, Chronic

GS-4321

Phase 2

Chronic Hepatitis Delta

ribavirin tablet

Phase 2

Hepatitis C, Chronic

Brexucabtagene Autoleucel (KTE-X19)

Phase 2

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Cidofovir

Phase 2

Cytomegalovirus Retinitis

hA20-humanized anti-CD20 antibody

Phase 2

Non-Hodgkin's Lymphoma

Febuxostat

Phase 2

Gout

TUB-040 + Carbo + BEV

Phase 2

Ovarian Cancer

GS-0938

Phase 2

Hepatitis C, Chronic

radiolabeled epratuzumab

Phase 2

Non-Hodgkin's Lymphoma

GS-1427

Phase 2

Ulcerative Colitis

Nelfinavir mesylate

Phase 2

HIV Infections

Entospletinib

Phase 2

Anemia

veltuzumab and milatuzumab

Phase 2

Lymphoma

Eleclazine

Phase 2

Ventricular Arrhythmia

High-dose methylprednisolone

Phase 2

Refractory Diffuse Large B Cell Lymphoma (DLBCL)

SEL

Phase 2

Diabetic Kidney Disease

Liposomal amphotericin B (AmBisome®) and sodium stibogluconate

Phase 2

Primary Visceral Leishmaniasis

Denikitug

Phase 2

HER2-negative

Adefovir dipivoxil and hepatitis B vaccination

Phase 2

Hepatitis B

Antiretroviral Therapy

Phase 2

HIV-1 Infection

Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)

Phase 2

HIV Infections

Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)

Phase 2

HIV Infections

Experimental PrEP:TAF/FTC once daily (weeks 0-26)

Phase 2

HIV Infections

Cilofexor Dose A

Phase 2

Primary Biliary Cholangitis

GS-5806

Phase 2

Respiratory Syncytial Virus Infections

Cilofexor

Phase 2

Primary Sclerosing Cholangitis

Miltefosine

Phase 2

Primary Visceral Leishmaniasis

Selonsertib

Phase 2

Alcoholic Hepatitis (AH)

VEL

Phase 2

Hepatitis C

hMN14 (labetuzumab)

Phase 2

Pancreatic Neoplasms

Abacavir sulfate

Phase 2

HIV Infections

EVG

Phase 2

HIV Infections

Granulocyte Colony-Stimulating Factor

Phase 2

Triple Negative Breast Cancer

Lanraplenib

Phase 2

Lupus Membranous Nephropathy

GS-9669

Phase 2

Chronic HCV Infection

GS-9256

Phase 2

HCV Infection

MBX-2044

Phase 2

Type 2 Diabetes Mellitus

Selgantolimod

Phase 2

Chronic Hepatitis B

Indinavir sulfate

Phase 2

HIV Infections

Zimberelimab (ZIM)

Phase 2

Lung Cancer

90Y-hPAM4

Phase 2

Pancreatic Cancer

• TF2 and 68 Ga-IMP-288

Phase 2

Medullary Thyroid Carcinoma

Emtricitabine/tenofovir (FTC/TDF (Truvada®))

Phase 2

HIV Infection

TMC435

Phase 2

Hepatitis C

Switch to E/C/FTC/TAF daily

Phase 2

HIV/AIDS

Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

Phase 2

Pre-Exposure Prophylaxis of HIV Infection

Epclusa

Phase 2

End Stage Renal Disease

PTM Cilofexor Dose A

Phase 2

Primary Biliary Cholangitis

PTM Cilofexor Dose B

Phase 2

Primary Biliary Cholangitis

IMMU-107 (hPAM4)

Phase 2

Pancreatic Cancer

Edecesertib

Phase 2

Cutaneous Lupus Erythematosus (CLE)

Hepatitis B virus (HBV) OAV Therapy

Phase 2

Chronic Hepatitis B

BSF 208075

Phase 2

Pulmonary Hypertension

VOX

Phase 2

Hepatitis C Virus Infection

tegobuvir capsule

Phase 2

Chronic Genotype 1a or 1b HCV Infection

Remdesivir (RDV)

Phase 2

COVID-19

TF2 - 68 Ga-IMP-288

Phase 2

HER2 Negative Breast Carcinoma Expressing CEA

Efavirenz

Phase 2

HIV Infections

VRC07523LS

Phase 2

HIV-1-infection

Sofosbuvir/Velpatasvir/Voxilaprevir

Phase 2

Chronic Hepatitis C

GS-3242

Phase 2

HIV-1 Infection

Cilofexor (CILO)/Firsocostat (FIR)

Phase 2

Nonalcoholic Steatohepatitis

CAP256V2LS

Phase 2

HIV-1-infection

Trastuzumab and Hyaluronidase-oysk

Phase 2

Her 2 Positive Breast Cancer

Trifluridine-Tipiracil

Phase 2

Advanced Microsatellite Stable Colorectal Cancer

Zydelig

Phase 2

Non Hodgkin Lymphoma

LDV/SOF FDC

Phase 2

Acute Hepatitis C

emtricitabine/tenofovir DF

Phase 2

Chronic Hepatitis B

Sofosbuvir and Velpatasvir

Phase 2

Hepatitis C

Probenecid

Phase 2

Cytomegalovirus Retinitis

Tenofovir disoproxil fumarate (tenofovir DF; TDF)

Phase 2

Chronic Hepatitis B

BIC

Phase 2

HIV-1 Infection

Frequently asked questions

What is in Gilead Sciences, Inc.'s drug pipeline?→

CatalystAlert tracks 337 drug candidates in Gilead Sciences, Inc.'s (GILD) pipeline across Phase 3, Phase 2, Approved. Its lead program is Lenacapavir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Gilead Sciences, Inc.'s next FDA catalyst?→

Gilead Sciences, Inc.'s (GILD) next tracked catalyst is a PDUFA date expected Feb 2, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track GILD biotech catalysts?→

Add GILD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Gilead Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply